DJIA 16,461.32 -153.49 -0.92%
NASDAQ 4,382.85 -36.63 -0.83%
S&P 500 1,927.11 -14.17 -0.73%
market minute promo

Gilead Sciences (NASDAQ: GILD)

106.09 -0.58 (-0.54%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GILD $106.09 -0.54%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $106.51
Previous Close $106.67
Daily Range $104.08 - $107.00
52-Week Range $63.50 - $110.64
Market Cap $160.4B
P/E Ratio 24.02
Dividend (Yield) $0.00 (0.0%)
Volume 13,680,680
Average Daily Volume 14,756,322
Current FY EPS $7.26





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary Rss Feed

Why Regulus Therapeutics Inc. Stock More Than Doubled

Regulus Therapeutics is today's best biotech stock as its shares more than doubled following the release of positive interim hepatitis C drug data.

Gilead's Hep C Dream Drug Faces Demanding Investors

Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results

Is Johnson & Johnson's Worst Nightmare Becoming Reality?

Johnson & Johnson has become a growth story on the back of strong pharmaceutical sales over the past two quarters. This trend looks like it is about to change with the approval of a rival's game-changing drug.

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results

Priceline Is On Sale

Gilead Sciences: Pricing, Politics And Profits

Gilead Sciences: Clear The Dockets And Settle With Merck Already

3 Drugs Critical to Johnson & Johnson's Future

Johnson & Johnson faces new threats to top selling drugs this year, but these three drugs may blunt the risk.

3 Drugs Stocks Pushing Industry Growth

See More GILD News...

GILD's Top Competitors

GILD $106.09 (-0.54%)
Current stock: GILD
AMGN $143.64 (-0.31%)
Current stock: AMGN
CELG $94.76 (-0.22%)
Current stock: CELG
$0.00 (0.00%)
Current stock: